AI Expert Exscientia Adds BMS To Big Pharma Client List
$50m Upfront, Potential Value Of Pact Is Over $1.2bn
BMS is impressed with Exscientia's projects with recently acquired Celgene and has signed up to use the UK firm's artificial intelligence platform to accelerate the discovery of small molecules in areas including oncology and immunology.
